Matrix Partners Leads $53M Series B Round In Chinese Biopharma Firm Adlai Nortye

For Digital Subscribers Only

Hangzhou-based biopharmaceutical company Adlai Nortye Biopharma announced that it has raised a US$53 million series B round from Matrix Partners China and other investors.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in

China Expert network

RELATED NEWS



LEAVE A REPLY